Efficacy, Safety, and Dose Response of STS01, a Topical Controlled Release Nanoparticle Formulation (Dithranol/Prosilic), in Adults with Mild to Moderate Patchy Alopecia Areata: A Randomized, Double-Blind, Multicenter, Phase 2 Trial

    April 2026 in “ medRxiv
    David J. Fleet, Andrew G. Messenger, Alyson Bryden, Matthew J Harris, Susan Holmes, Paul Farrant, Brian Leaker, Anita Takwale, Michelle Oakford, Manjit Kaur, Megan Mowbray, A. E. Macbeth, Pikun Gangwani, Maria A Gkini, Vicky Jolliffe
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →